Apoptotic effect of As2S2 on K562 cells and its mechanism

Acta Pharmacologica Sinica

Volumn 23, Issue 11, 2002, Pages 991-996

  Li, Jun E ^a   Wu, Wei Li ^a   Wang, Zhen Yi ^a   Sun, Guan Lin ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Arsenicals; Bcr Abl fusion proteins; Chronic myeloid leukemia

Indexed keywords

BCR ABL PROTEIN; DNA FRAGMENT; ORGANOARSENIC DERIVATIVE; PROTEIN TYROSINE KINASE; ARSENIC DISULFIDE; MESSENGER RNA; SULFIDE;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MONONUCLEAR CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; WESTERN BLOTTING; BIOSYNTHESIS; CELL DIVISION; CELL SURVIVAL; DRUG EFFECT; GENETICS; METABOLISM; ONCOGENE; PATHOLOGY;

APOPTOSIS; ARSENICALS; CELL DIVISION; CELL SURVIVAL; FUSION PROTEINS, BCR-ABL; GENES, ABL; HUMANS; K562 CELLS; LEUKEMIA, MYELOID, CHRONIC; LEUKOCYTES, MONONUCLEAR; PROTEIN-TYROSINE KINASES; RNA, MESSENGER; SULFIDES;

EID: 0036843652     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-6.
2. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90: 3691-8.
3. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-42.
4. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-7.
5. Watzinger F, Gaiger A, Karlic H, Becher R, Pillwein K, Lion T. Absence of N-ras mutations in myeloid and lymphoid blast crisis of chronic myeloid leukemia. Cancer Res 1994; 54: 3934-8.
6. Morrison VA. Chronic leukemias. CA Cancer J Clin 1994; 44: 353-77.
7. Brincker H. Population-based age-and sex-specific incidence rates in the 4 main types of leukemia. Scand J Haematol 1982; 29: 241-9.
8. Call TG, Phyliky RL, Noel P, Habermann TM, Beard CM, O'Fallon WM, et al. Incidence of leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clin Proc 1994; 69: 315-8.
9. Fialkow PJ. Cell lineages in hematopoietic neoplasia studied with glucose-6-phosphate dehydrogenase cell markers. J Cell Physiol Suppl 1982; 1: 37-43.
10. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83: 1179-87.
11. Puccetti E, Guller S, Orleth A, Bruggenolte D, Hoelzer D, Ottmann OG, et al. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer Res 2000; 60: 3409-13.